(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 November 2009 (26.11.2009)

PCT

(10) International Publication Number
WO 2009/143285 A3

(51) International Patent Classification:
A61K 38/22 (2006.01)

(21) International Application Number:
PCT/US2009/044727

(22) International Filing Date:
20 May 2009 (20.05.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/054,883 21 May 2008 (21.05.2008) US

(71) Applicant *(for all designated States except US)*: **AMYLIN PHARMACEUTICALS, INC.** [US/US]; 9360 Towne Centre Drive, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FINEMAN, Mark** [US/US]; Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121 (US). **MACCONELL, Leigh** [US/US]; Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121 (US). **TAYLOR, Kristin** [US/US]; Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121 (US).

(74) Common Representative: **AMYLIN PHARMACEUTICALS, INC.**; 9360 Towne Centre Drive, Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

[Continued on next page]

(54) Title: EXENDINS TO LOWER CHOLESTROL AND TRIGLYCERIDES

Figure 1



(57) Abstract: Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co- glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microshperes encapsulating the exenatide.

WO 2009/143285 A3

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report: 14 January 2010

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 09/44727

A. CLASSIFICATION OF SUBJECT MATTER
IPC(8) - A61K 38/00 (2009.01)
USPC - 514/12
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
USPC- 514/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
PubWEST (USPT, PGPB, EPAB, JPAB), Google Patent/Scholar: exendin, long acting, sustained release, cholesterol, triglyceride, atherosclerosis, dyslipidemia, geometric mean

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 2006/0183677 A1 (Young et al.) 17 Aug 2006 (17.08.2006) para [0010], [0012]-[0013], [0016], [0052], [0095], [0118], [0126]-[0127], [0181]	1, 3-7, 9-15, 17 ---------- 2, 8, 16, 22
Y	US 2008/0057131 A1 (Dasch et al.) 06 Mar 2008 (06.03.2008) para [0006], [0157], [0208]	2, 18-32
Y	WO 2007/024700 A1 (Fineman et al.) 01 Mar 2007 (01.03.2007) para [014], [017]-[019], [022], [025], [030], [0217], [0219], [0221], [0234]	8, 16, 18-21, 23-32

☐ Further documents are listed in the continuation of Box C. ☐

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
24 July 2009 (24.07.2009)	05 AUG 2009
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

Form PCT/ISA/210 (second sheet) (April 2007)